Priti Bahety1, Thi Hai Van Nguyen1, Yanjun Hong1, Luqi Zhang1, Eric Chun Yong Chan2, Pui Lai Rachel Ee3. 1. Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Republic of Singapore. 2. Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Republic of Singapore. phaccye@nus.edu.sg. 3. Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Republic of Singapore. phaeplr@nus.edu.sg.
Abstract
PURPOSE: Over the past few decades, docosahexaenoic acid (DHA) has gained special attention for management of cholesterol-associated metabolic disorders and neurodegenerative diseases such as Alzheimer's disease (AD) owing to its neuroprotective, anti-inflammatory and hypolipidemic properties. Several epidemiological studies have reported the effect of DHA in reducing the risk of developing AD by lowering cholesterol. Hypercholesterolemia is a pro-amyloidogenic factor influencing the enzymatic processing of amyloid-β precursor protein (AβPP) to toxic β-amyloid. However, the mechanism by which DHA modulates the cholesterol pathway has not been established. Thus, the objective of this study was to investigate the mechanism of regulation of cholesterol metabolism by DHA in an AβPP695 overexpressing AD cell model. METHODS: A gas chromatography/mass spectrometry method was developed and validated for the targeted profiling of 11 cholesterol metabolites in DHA-treated Chinese hamster ovary wild-type (CHO-wt) and AβPP695 overexpressing (CHO-AβPP695) cells. The differential metabolite profiles between DHA- and vehicle-treated groups were further analyzed using fold change values of the ratio of concentration of metabolites in CHO-AβPP695 to CHO-wt cells. Effect of DHA on key rate-limiting enzymatic activities within the cholesterol pathway was established using biochemical assays. RESULTS: Our results showed that DHA reduced the levels of key cholesterol anabolites and catabolites in CHO-AβPP695 cells as compared to CHO-wt cells. Further enzymatic studies revealed that the cholesterol-lowering effect of DHA was mediated by regulating HMG-CoA reductase and squalene epoxidase enzyme activities. CONCLUSION: We demonstrate for the first time the dual effects of DHA in inhibiting HMG-CoA reductase and squalene epoxidase and modulating the sterol biosynthesis axis of the cholesterol pathway in AβPP695 overexpressing AD. Our novel findings underscore the potential of DHA as a multi-target hypocholesterolemic agent for the prophylaxis of AD and other cholesterol-associated diseases.
PURPOSE: Over the past few decades, docosahexaenoic acid (DHA) has gained special attention for management of cholesterol-associated metabolic disorders and neurodegenerative diseases such as Alzheimer's disease (AD) owing to its neuroprotective, anti-inflammatory and hypolipidemic properties. Several epidemiological studies have reported the effect of DHA in reducing the risk of developing AD by lowering cholesterol. Hypercholesterolemia is a pro-amyloidogenic factor influencing the enzymatic processing of amyloid-β precursor protein (AβPP) to toxic β-amyloid. However, the mechanism by which DHA modulates the cholesterol pathway has not been established. Thus, the objective of this study was to investigate the mechanism of regulation of cholesterol metabolism by DHA in an AβPP695 overexpressing AD cell model. METHODS: A gas chromatography/mass spectrometry method was developed and validated for the targeted profiling of 11 cholesterol metabolites in DHA-treated Chinese hamster ovary wild-type (CHO-wt) and AβPP695 overexpressing (CHO-AβPP695) cells. The differential metabolite profiles between DHA- and vehicle-treated groups were further analyzed using fold change values of the ratio of concentration of metabolites in CHO-AβPP695 to CHO-wt cells. Effect of DHA on key rate-limiting enzymatic activities within the cholesterol pathway was established using biochemical assays. RESULTS: Our results showed that DHA reduced the levels of key cholesterol anabolites and catabolites in CHO-AβPP695 cells as compared to CHO-wt cells. Further enzymatic studies revealed that the cholesterol-lowering effect of DHA was mediated by regulating HMG-CoA reductase and squalene epoxidase enzyme activities. CONCLUSION: We demonstrate for the first time the dual effects of DHA in inhibiting HMG-CoA reductase and squalene epoxidase and modulating the sterol biosynthesis axis of the cholesterol pathway in AβPP695 overexpressing AD. Our novel findings underscore the potential of DHA as a multi-target hypocholesterolemic agent for the prophylaxis of AD and other cholesterol-associated diseases.
Entities:
Keywords:
Amyloid β-precursor protein (AβPP); Cholesterol; Docosahexaenoic acid (DHA); Gas chromatography; HMG-CoA reductase; Metabonomics; Squalene epoxidase
Authors: Bernhard Lindenthal; Thomas Bertsch; Klaus Fassbender; Mark Stroick; Sandra Kühl; Dieter Lütjohann; Klaus von Bergmann Journal: Metabolism Date: 2002-04 Impact factor: 8.694
Authors: Marcus O W Grimm; Johanna Kuchenbecker; Sven Grösgen; Verena K Burg; Benjamin Hundsdörfer; Tatjana L Rothhaar; Petra Friess; Martijn C de Wilde; Laus M Broersen; Botond Penke; Mária Péter; László Vígh; Heike S Grimm; Tobias Hartmann Journal: J Biol Chem Date: 2011-02-15 Impact factor: 5.157
Authors: S Li; J Deng; H Hou; J Tian; B Giunta; Y Wang; D Sawmiller; A Smith; P R Sanberg; D Obregon; T Mori; J Tan Journal: Cell Death Dis Date: 2014-08-14 Impact factor: 8.469
Authors: M Orešič; T Hyötyläinen; S-K Herukka; M Sysi-Aho; I Mattila; T Seppänan-Laakso; V Julkunen; P V Gopalacharyulu; M Hallikainen; J Koikkalainen; M Kivipelto; S Helisalmi; J Lötjönen; H Soininen Journal: Transl Psychiatry Date: 2011-12-13 Impact factor: 6.222
Authors: Priti Bahety; Yee Min Tan; Yanjun Hong; Luqi Zhang; Eric Chun Yong Chan; Pui-Lai Rachel Ee Journal: PLoS One Date: 2014-02-27 Impact factor: 3.240